NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Indicator Equality Impact Assessment

### Topic: Vaccinations and immunisations (NM201)

* 1. Have any potential equality issues been identified during the development process?

Zostavax is the only shingles vaccine available in the UK and this contains porcine gelatine. Some faith groups may not consider a vaccine containing porcine products to be acceptable. [Public Health England have published information describing how and why porcine gelatine is used in vaccines.](https://www.gov.uk/government/publications/vaccines-and-porcine-gelatine)

* 1. Have any population groups, treatments or settings been excluded from coverage by the indicator? Are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

No populations groups, treatments or settings have been excluded from coverage by the indicators.

* 1. Does the indicator make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Some faith groups may not consider a vaccine containing porcine products to be acceptable. There is no alternative vaccine available. [Public Health England have published information describing how and why porcine gelatine is used in vaccines.](https://www.gov.uk/government/publications/vaccines-and-porcine-gelatine)

* 1. Is there potential for the indicator to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The indicators do not have the potential to have an adverse impact on people with disabilities.

Completed by lead technical analyst: Charlotte Fairclough

Date September 2020

Approved by NICE quality assurance lead: Craig Grime

Date September 2020

© NICE [2020]. All rights reserved. Subject to [Notice of rights](https://www.nice.org.uk/terms-and-conditions#notice-of-rights).